Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...

Cancer is a complex condition marked by the uncontrolled growth of cells in the body. When this process begins in the lungs, ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...

University of Alberta researchers have developed a new molecular imaging test that could lead to improved diagnosis of lung ...

The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...

Bayer initiates phase II panSOHO study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumours: Berlin Wednesday, March 5, 2025, 09:00 Hrs [IST] Bayer announced t ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end ...

for patients with non-small cell lung cancer (NSCLC). This coverage applies to patients with stage I-III NSCLC with ...